Single Arm, Multicenter, Open and Dose-escalation Clinical Study on Safety, Tolerance, and Efficacy of GC301, an AAV-Delivered Gene Transfer Therapy in Patients With Infantile-onset Pompe Disease
Latest Information Update: 07 Nov 2023
At a glance
- Drugs GC-301 (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
Most Recent Events
- 11 Oct 2022 New trial record